STOCK TITAN

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

(Neutral)
(Neutral)
Tags
earnings date

22nd Century Group (Nasdaq: XXII) will report first quarter 2026 results on May 7, 2026. A press release will be issued at 6:00 AM ET, followed by a live webcast at 8:00 AM ET with CEO Larry Firestone and CFO Dan Otto.

The webcast and archived replay are available on the company’s Events page. The company highlights its FDA‑authorized VLN® cigarette, made with proprietary tobacco that contains 95% less nicotine than traditional cigarettes.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – XXII

-27.59%
55 alerts
-27.59% Session close to close
-21.5% Trough in 2 hr 40 min
$1.52M Market Cap
0.1x Rel. Volume

In the May 4 session, XXII declined 27.59%, reflecting a significant negative market reaction. Argus tracked a trough of -21.5% from its starting point during tracking. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -27.6% in the session following this news. The decline reflects selling pressure a...
Analysis

The stock dropped -27.6% in the session following this news. The decline reflects selling pressure ahead of Q1 2026 results despite this being only an earnings-date notice. The prior earnings-date release saw a smaller -1.68% move, whereas today’s -12.18% drop is considerably steeper. With an effective $250,000,000 shelf and a $1,840,000 ATM program in place, the market may also be sensitive to the company’s ability to issue additional securities alongside upcoming financial disclosures.

Key Figures

Webcast time: 8:00 AM ET Press release time: 6:00 AM ET Industry experience: 28 years +2 more
5 metrics
Webcast time 8:00 AM ET Q1 2026 results webcast on May 7, 2026
Press release time 6:00 AM ET Q1 2026 results press release on May 7, 2026
Industry experience 28 years Company states it has led fight against harms of smoking
Nicotine reduction (plants) 95% less nicotine Proprietary non-GMO reduced nicotine tobacco plants vs traditional plants
Nicotine reduction (VLN) 95% less nicotine VLN cigarettes vs traditional cigarettes

Previous Earnings date Reports

1 past event · Latest: Mar 23 (Neutral)
Same Type Pattern 1 events
Date Event Sentiment 24h Move Catalyst
Mar 23 Earnings date notice Neutral -1.7% Announced timing and webcast details for Q4 and full-year 2025 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited earnings-date history shows a modest negative move on the prior announcement.

Recent Company History

Recent news has focused on VLN® growth plans, reduced‑nicotine product development and capital structure moves. The prior earnings date notice on Mar 23, 2026 preceded Q4 and full‑year 2025 results and led to a -1.68% move. Subsequent filings added a significant securities shelf and ATM capacity. Today’s Q1 2026 earnings‑date notice continues the pattern of scheduling early‑morning releases followed by management webcasts.

Key Terms

non-GMO, alkaloid biosynthesis, fda
3 terms
non-GMO medical
"Our proprietary non-GMO reduced nicotine tobacco plants were developed..."
Non-GMO means a product or ingredient was produced without genetic modification techniques — the plant or organism’s DNA has not been intentionally altered in a laboratory. Investors care because non-GMO labeling can affect consumer demand, price premiums, shelf access and supply-chain cost; think of it like an organic or “no added hormones” label that can open certain markets, change margins, and create reputational risk or advantage for companies.
alkaloid biosynthesis medical
"technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant..."
Alkaloid biosynthesis is the set of natural chemical steps inside plants, fungi or microbes that build alkaloids — a class of nitrogen-containing molecules that include many medicines, stimulants and defensive toxins. For investors, controlling or scaling these pathways is like improving a factory assembly line: it affects how much of a valuable compound can be produced, the cost and consistency of supply, intellectual property and regulatory or safety risks.
fda regulatory
"Our VLN cigarette is the only low nicotine combustible cigarette authorized by the FDA..."
The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MOCKSVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction,, will host a webcast on Thursday, May 7, 2026, at 8:00 AM ET to discuss its 2026 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the first quarter and update plans for the 2026 year.

The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website, at https://ir.xxiicentury.com/events. Please access the website at least 10 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

FDA Authorized

Our VLN® cigarette is the only low nicotine combustible cigarette authorized by the FDA in the United States.

VLN® is a registered trademark of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
investorrelations@xxiicentury.com
214-597-8200


FAQ

When will 22nd Century (XXII) announce Q1 2026 results and how can I listen?

They will issue a press release on May 7, 2026 at 6:00 AM ET and host a webcast at 8:00 AM ET. According to the company, the live and archived webcast are available on its Events page and investors should register at least 10 minutes early.

Who will present on the 22nd Century Q1 2026 webcast for XXII?

CEO Larry Firestone and CFO Dan Otto will review Q1 2026 results during the webcast. According to the company, they will discuss financial results, first‑quarter progress, and plans for the 2026 year.

What timing and access details does 22nd Century provide for the May 7, 2026 webcast (XXII)?

The webcast begins May 7, 2026 at 8:00 AM ET with a press release released at 6:00 AM ET. According to the company, attendees should access the Events page to register and download any required software beforehand.

Is 22nd Century's VLN cigarette FDA authorized and what is its nicotine level (XXII)?

Yes. According to the company, VLN is the only FDA‑authorized low nicotine combustible cigarette in the U.S. and uses tobacco containing 95% less nicotine than traditional cigarettes.

Where can investors find 22nd Century (XXII) investor materials and the archived webcast after May 7, 2026?

Investor materials and the archived webcast will be available on the company’s Events page on its investor relations website. According to the company, the replay will remain accessible after the live presentation.